Table 2.
Case series: clinicopathological features, molecular characteristics, and outcomes.
| Patients | Age | Primary Tumor | PS | Best Response | PFS (Months) | OS (Months) | Early Progression | Patient Status 1 | Genomic Signature |
|---|---|---|---|---|---|---|---|---|---|
| Case 1 | 62 | Oral cavity | 1 | PD | 2 | 6 | Yes | DOD | TMB-intermediate 8 mut/MB MSI-stable |
| Case 2 | 65 | Larynx | 1 | PD | 1 | 21 | Yes | ALIVE | TMB 6 muts/MB MSI-stable |
| Case 3 | 76 | Larynx | 1 | PD | 2 | 2 | Yes | DOD | TMB 6 muts/MB MSI-stable |
| Case 4 | 65 | Oral cavity | 1 | PD | 2 | 11 | Yes | DOD | TMB 3 muts/MB MSI-stable |
| Case 5 | 53 | Larynx | 1 | PD | 1 | 3 | Yes | DOD | TMB 4 muts/MB MSI-stable |
| Case 6 | 52 | Oropharynx | 1 | SD | 5 | 6 | No | DOD | TMB 5 muts/MB MSI-stable |
| Case 7 | 63 | Oral cavity | 1 | SD | 6 | 7 | No | DOD | TMB 3 muts/MB MSI-stable |
| Case 8 | 71(F) | Larynx | 0 | PR | 33 | 33 | No | ALIVE | TMB 30 muts/MB MSI-stable |
| Case 9 | 67 | Larynx | 0 | PR | 20 | 39 | No | ALIVE | TMB 15 muts/MB MSI-stable |
| Case 10 | 46(F) | Oral cavity | 1 | PR | 4 | 5 | No | DOD | TMB 1 muts/MB MSI-stable |
1 At the last follow-up visit; DOD: death of disease; PFS: progression free survival; OS: overall survival; SD: stable disease; PD: progressive disease; PR: partial response; TMB: tumor mutational burden; MSI: microsatellite instability.